Skip to content

ResMed

US · RMD #644 by market cap Listed 1970
235.63 -1.25 -0.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).
    PR Newswire · 2026/11/10
  • Rating change
    Stifel Maintains ResMed(RMD.US) With Hold Rating
    Market Newswire · 2026/9/25
  • A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $260 to $288
    Market Newswire · 2026/10/31
  • UBS Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
    TipRanks · 2026/10/21
  • Citi Maintains ResMed(RMD.US) With Hold Rating, Maintains Target Price $270
    Market Newswire · 2026/11/2
  • Company notice
    ResMed Inc: LR 1.15.3 Compliance
    ASX · 2026/8/28
  • Rating change
    ResMed Price Target Raised 1.5% to A$47.50/Share by Macquarie
    Dow Jones · 2026/11/2
  • Mizuho Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $240
    Market Newswire · 2026/10/13
  • Company notice
    8-K: Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
    SEC · 2026/5/1
  • Rating change
    Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Gets a Buy From Canaccord Genuity
    TipRanks · 2026/9/29
  • Company notice
    8-K: Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
    SEC · 2026/8/7
  • Rating change
    Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Receives a Buy From Ord Minnett
    TipRanks · 2026/10/5
  • Rating change
    Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Gets a Hold From Citi
    TipRanks · 2026/10/19
  • Company notice
    8-K: Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
    SEC · 2026/1/30
  • Rating change
    ResMed Price Target Raised 3.6% to US$233.00/Share by Morgan Stanley
    Dow Jones · 2026/10/22
  • Rating change
    ResMed Cut to Accumulate From Buy by Morgans RMD.AU
    Dow Jones · 2026/11/3
  • Company notice
    8-K: Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
    SEC · 2026/10/30
  • Rating change
    ResMed Price Target Raised 3.6% to A$37.50/Share by Barrenjoey
    Dow Jones · 2026/11/2
  • Rating change
    Citi Sticks to Its Hold Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
    TipRanks · 2026/10/16
  • Rating change
    Stifel Maintains ResMed(RMD.US) With Hold Rating, Announces Target Price $235
    Market Newswire · 2026/10/2
  • ResMed Target Price Raised 1.3% to A$40.00/Share by MorgansRMD.AU
    Dow Jones · 2026/11/3
  • Don't Lose Sleep Over GLP-1s: Why ResMed Stock Is a Bargain -- Barrons.com
    Barron's · 2026/11/5
  • Company notice
    8-K: Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
    SEC · 2025/10/31
  • Morgan Stanley Sticks to Their Hold Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
    TipRanks · 2026/10/23
  • Rating change
    Citi Maintains ResMed(RMD.US) With Hold Rating, Raises Target Price to $240
    Market Newswire · 2026/9/10

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.

ResMed discussion 0 comments

Add a comment